Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 587.43% and currently trading at $909.00.
The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.
However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond.
That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.
Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future.
Eli Lilly's Recent Performance: A Rollercoaster Ride?
Eli Lilly’s stock has seen a slight decline of 2.57% over the past month. Investors are keenly focused on the company’s upcoming earnings report. Eli Lilly is anticipated to report a substantial increase in earnings per share, a staggering 4,430% compared to the previous year.
Eli Lilly: A Company on the Rise
How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers:
Revenue and Net Income in Billions
Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price.
For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.
The current Wall Street consensus 1-year price target of Eli Lilly stock is $898, which is 1.21% lower than today’s price of $909.00. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.
24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows:
Eli Lilly Stock Price Prediction: 2025 to 2030
Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple.
*Revenue and net income reported in billions *
We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.
For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.
Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.
With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.
By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.
Price Target: $1850.00 ## Upside: 103.52%
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.
Final Thoughts: Is Eli Lilly a Buy?
Eli Lilly has a strong track record of delivering innovative and profitable drugs. The company has several promising new drugs in its pipeline. We believe these factors will continue to drive growth and support a higher stock price in the coming years.
Our price targets for Eli Lilly stock are based on a combination of factors, including revenue growth, net income growth, and price-to-earnings multiples. However, it is important to note that these are just estimates and there is always the possibility that the actual stock price could deviate from our projections.
As always, it’s essential to conduct your own research and consult with a financial advisor before making any investment decisions.
